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Abstract
Autophagy is an evolutionarily conserved intracellular degradative function that is important for 
liver homeostasis. Accumulating evidence suggests that autophagy is deregulated during the 
progression and development of alcoholic and non-alcoholic liver diseases. Impaired autophagy 
prevents the clearance of excessive lipid droplets (LDs), damaged mitochondria, and toxic protein 
aggregates, which can be generated during the progression of various liver diseases, thus 
contributing to the development of steatosis, injury, steatohepatitis, fibrosis, and tumors. In this 
review, we look at the status of hepatic autophagy during the pathogenesis of alcoholic and non-
alcoholic liver diseases. We also examine the mechanisms of defects in autophagy, and the hepato-
protective roles of autophagy in non-alcoholic fatty liver disease (NAFLD) and alcoholic liver 
disease (ALD), focusing mainly on steatosis and liver injury. Finally, we discuss the therapeutic 
potential of autophagy modulating agents for the treatment of these two common liver diseases.
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1. Introduction
Basal autophagy occurs in the liver to allow constitutive turn-over of cytosolic components.1 
As an adaptive process, a number of stressors, including starvation, growth factor depletion, 
oxidative injury, and chemicals can stimulate autophagy. Among these stressors, starvation 
or fasting is the best-understood stimulus for autophagy. How cells sense the need to boost 
in autophagic activity has not yet well-defined. It probably depends on the nature of the 
stress. For example, amino acid starvation is perceived through the lysosomal nutrient 
sensing system to inactivate mammalian target of rapamycin complex 1 (mTORC1), so 
autophagy is de-repressed.2 Once autophagy signal is induced, autophagy machinery kicks 
in, leading to the formation of the autophagosome membrane, its elongation, cargo 
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engulfment and trafficking to the lysosome, and ultimately the breakdown of the 
components inside the lysosome (Fig. 1).3
2. Concepts and signaling regulators of autophagy
2.1. General concepts of autophagy
The induction of autophagy requires a set of conserved factors called “autophagy-related 
(ATG)” proteins that function as complexes to induce autophagy.4 The ATG factors are 
grouped into functional units that includes unc-51 like autophagy activating kinase 1 
(ULK1) tetrameric kinase complex (ULK1, RB1-inducible coiled-coil protein 1 (FIP200/
RB1CC1), ATG13L, and ATG101), the class III phosphatidylinositol 3-phosphate kinase 
complex (PI3KC3) (VPS34, beclin-1, p115, and ATG14 or UV radiation resistance-
associated gene protein (UVRAG)), WD-repeat protein interacting with phosphoinositides 
(WIPI) family, the ATG9A cycling system, the two conjugation systems (for ATG12/ATG5/
ATG16 and the ATG8 family members), and the activating E1-like or E2-like enzymes 
(ATG7, ATG10, ATG3 required for two conjugation processes of ATG16-ATG5/12 and 
LC3-phosphatidylethanolamine (PE)/LC3-II).
In mammalian cells, autophagy begins with the formation of an expanding double-
membranous, cup-shaped structure, called phagophore, the edges of which extend and 
sequester cytosolic components to form autophagosome vesicles. The phagophore 
membrane may be derived from the endoplasmic reticulum (ER), the mitochondria, the 
Golgi apparatus, or the plasma membrane.5 Formation of autophagosomes is the 
morphological signature of the induction of autophagy. Autophagosomes then fuse with 
lysosomes to deliver and break down its contents by lysosomal proteases.6
The initiation and formation of phagophore begin with the activation of the ULK1 kinase 
complex and the formation of ULK1 puncta at a discrete location on the ER. The activated 
ULK protein complex then recruits the VPS kinase complex to the phagophore, and 
phosphorylates the class III PI3K together with the ULK1 complex, generating a local pool 
of phosphatidylinositol 3-phosphate. This alteration in lipid composition changes the 
membrane curvature, further expands the phagophore, and recruits the oligomers of ATG12-
conjugated ATG5 in complex with ATG16L. The formation of the ATG12-ATG5-ATG16 
complex is mediated by ATG7 and ATG10. The ATG12-ATG5-ATG16 complex is then 
recruited to the autophagosome membrane. This complex facilitates the lipidation of 
ATG8/LC3 via conjugation to PE on the autophagosome membrane. The latter event causes 
further expansion and enclosure of the autophagosome membrane.
Autophagosomes are generally formed around the peripheral regions of cells, and hence, 
they are transported along microtubules towards the perinuclear regions, where lysosomes 
reside for the final degradation.7 The lysosome contains a repertoire of degradative enzymes, 
such as proteases, nucleases and glycosidase. The degradation products, including amino 
acids, sugars and lipids/free fatty acids (FFAs), are transported out of the autolysosome via 
the lysosomal permeases for reutilization of these simple biomolecules. During termination 
step of autophagy, lysosome is regenerated through autophagic lysosome reformation 
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(ALR). During ALR, tubules extrude from autolysosomes, and small proto-lysosomal 
vesicles are regenerated. Eventually, proto-lysosome matures into functional lysosomes.8,9
Autophagy can also perform selective recognition and sequestration of cargo through a 
process, called selective autophagy. Depending on the nature of the sequestration of 
intracellular substrates, autophagy is termed mitophagy (damaged or dysfunctional 
mitochondria), proteophagy (protein aggregates), pexophagy (peroxisomes), lipophagy 
(excessive lipid droplets (LDs)), ferritinophagy (ferritin), or xenophagy (intracellular 
microorganisms).10,11 Selective autophagy relies on a plethora of selective autophagy 
receptors (SARs), such as p62/SQSTM1, neighbor of BRCA1 gene 1 (NBR1), NDP52 
(nuclear domain 10 protein 52 kDa), and optineurin (OPTN). SAR generally binds to the 
cargo (often ubiquitinated) and key components of the autophagy machinery, especially the 
LC3 protein.10,12
In the context of intracellular trafficking pathways, conceptually, autophagy appears to 
function as a parallel pathway that carries intracellular cargo into the lysosome, in a similar 
fashion to the hepatocellular endocytic pathway, which internalizes and transports 
extracellular cargo (e.g. low density lipoprotein (LDL)/LDL receptor) into the lysosome. 
There could be a potential cross-talk between autophagy and the endocytic pathway, because 
(i) specific compartments are shared between them, (ii) both contribute to cellular 
proteolysis, (iii) in both cases the degradative executioner components is retained by 
lysosomal compartment and (iv) both pathways require regulated trafficking of vesicles that 
interact in a dynamic way, undergoing fission and fusion as part of their maturation process. 
Notably, whether autophagy or endocytic pathway related vesicular trafficking really 
impacts the lysosomal function, number, or structure is unknown.
2.2. Autophagy signaling regulators: mTORC1, AMP-activated protein kinase (AMPK), 
and transcription factor EB (TFEB)
Given the important roles of autophagy in the survival mechanism of mammalian cells, it is 
not surprising that alterations of autophagy occur in response to extracellular or intracellular 
stress, such as starvation, growth factor deprivation, ER stress, and pathogen infection.13 
How different external stressors activate the same autophagy executioner complex is an 
interesting issue. We will discuss autophagy signaling in reference to the cellular nutrient 
status.
In liver, autophagy gets activated not only during starvation, but this process gets activated 
daily between meals to provide essential nutrient components and guarantee periodical 
cellular clearance. One of the best-characterized regulators of autophagy signaling is the 
mTORC1. In general, mTORC1 activation suppresses autophagy, whereas the suppression 
of mTORC1 activates autophagy.2,14 mTORC1 phosphorylates and actively sequesters the 
ULK1 in a complex with ATG13 and FIP200 in an inactive state. Nutrient starvation 
increases the cellular AMP/ATP ratio, activating cellular energy sensor AMPK, which 
inhibits mTORC1 through three molecular mechanisms: (i) direct phosphorylation of 
mTORC1, (ii) phosphorylation of tuberous sclerosis 2 (TSC2) and Raptor (mTORC1 
component) to inhibit mTORC1, and (iii) phosphorylation of ULK1 at different residue to 
activate ULK1 kinase complex. All of these three different phosphorylation events inhibit 
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mTORC1 activity and hence reduce ULK1 phosphorylation and promote its release from 
mTORC1. ULK1 kinase complex is then activated to recruit other autophagy proteins and 
induce autophagy.2,14 With the complete execution of autophagy process, lysosomal 
degradation of cellular components release the nutrients, including amino acids, which can 
reactivate mTORC1 and thereby attenuate the ULK1 dependent autophagy.14 This inhibitory 
feedback prevents excessive autophagy which may lead to apoptosis.
In addition to mTORC1 and AMPK mediated regulation of autophagy at the signaling level, 
the longer-term transcriptional regulation of autophagy is carried out by TFEB. TFEB is a 
basic helix-loop-helix (bHLH) leucine zipper transcription factor of the NITF family.15 It is 
a master transcriptional regulator of lysosomal biogenesis and autophagy. Under nutrient-
rich conditions, mTORC1 phosphorylates TFEB at Ser211 and retains TFEB in the cytosol 
via the interaction with the members of the YWHA (14–3-3) family of proteins.16–18 
However, nutrient deprivation leads to mTORC1 inhibition, dephosphorylation of S211 and 
its rapid translocation to the nucleus to initiate the downstream transcription of autophagy 
genes.19 There, TFEB induces its own expression and also binds directly to the promoters of 
a multitude of autophagy-related genes and drives rapid expression of autophagy genes such 
as ATG4, ATG9, LC3, p62, UVRAG and Wili1, which are involved in cargo sequestration, 
autophagosome membrane closure, and fusion with the lysosome. Besides, TFEB induces 
lysosome biogenesis, thus favoring autophagy degradation.17 Approximately 96 lysosomal 
genes termed the coordinated lysosomal expression and regulation (CLEAR) genes are 
regulated for lysosomal biogenesis and function. Interestingly, lysosomal Ca2+ release 
through mucolipin 1 (MCOLN1), which activates cytosolic calcineurin, is required for the 
dephosphorylation of TFEB mediated autophagy induction and lysosomal biogenesis.20 
Nuclear localization and activity of TFEB are also regulated by phosphorylation (Ser142) by 
the extracellular signal-regulated kinase-2 (Erk2), the activity of which is tuned by the levels 
of extracellular nutrients.17 In support of these observations, overexpression of TFEB is 
sufficient to induce autophagy and liver-directed TFEB expression corrects hepatic disease 
by increased SERPINA1 polymer degradation via enhanced autophagy flux.21 Similar 
protective effect of TFEB overexpression has been noted in various genetic and dietary 
models of obesity and alcoholic liver disease (ALD) models.22,23
Next, we will detail the roles of autophagy in the pathogenesis of alcoholic and non-
alcoholic fatty liver diseases. Basically, in the following section, we will take account of the 
autophagy-related basic questions, for example, what the status of autophagy is and what the 
molecular mechanism of alteration in autophagy in alcoholic and non-alcoholic liver 
diseases is. We will also discuss the role of autophagy in disease pathogenesis, particularly 
focusing on liver injury and steatosis. Finally, we will describe the current therapeutic 
potential of autophagy process for these two common liver diseases.
3. Autophagy in non-alcoholic fatty liver disease (NAFLD)
In NAFLD, hepatocyte has an excessive accumulation of triglycerides (TGs) and 
cholesterols in LDs. Autophagy can regulate the hepatocellular lipid accumulation by 
selective degradation.24 Based on this rationale, autophagy has been implicated to play a 
protective role during NAFLD. Hepatic autophagy can be inhibited or decreased in genetic 
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and dietary rodent models of NAFLD. Similar observations have been made in human liver 
samples that have been diagnosed with non-alcoholic steatohepatitis (NASH), which is 
pathologically more advanced than NAFLD. Increased accumulation of LC3-II and p62 
were observed in patients diagnosed with NASH.25 Interestingly, the accumulation of LC3-
II and p62 correlates positively with the severity of the disease.25,26 Autophagy dysfunction 
is also associated with cathepsins expression and hence lysosomal function in livers from 
patients with NAFLD.27
3.1. Autophagy status in NAFLD
The current consensus is that autophagy is decreased in the fatty hepatocyte. Based on the in 
vitro studies in hepatic cell lines and the in vivo high fat diet (HFD) feeding model, 
autophagosomes accumulate in hepatic cells. The increase in autophagosomes is due to the 
blocking of the fusion between autophagosomes and lysosomes.28 Consistent with this 
observation, in NAFLD, there is a prominent accumulation of insoluble protein inclusions 
containing p62 and ubiquitinated protein aggregates, which are substrates of autophagy.29 
Thus, blockade of autophagy flux (impaired lipophagy) probably further increases the 
intracellular fat accumulation. This vicious cycle of fat accumulation (due to excessive 
intake) and impairments in autophagic flux results in the development of hepatic steatosis. 
Whether blockade of autophagic flux is a major contributing factor to hepatic steatosis or 
merely a bystander effect of intracellular lipid accumulation is less clear. Moreover, the 
impact of autophagic dysregulation in the development and progression from steatosis to the 
steatohepatitis (NASH) is also undetermined.
3.2. Mechanism of autophagy deregulation in NAFLD
There are potentially four major mechanisms that may account for the impairment of 
autophagy in NAFLD. They are discussed below.
3.2.1. Downregulation of autophagy proteins—A decrease in the expression of key 
autophagy molecules, such as ATG7, can reduce autophagy process.30 Abnormal activation 
of proteases, such as calpain-2, can also reduce autophagy proteins levels, such as ATG3, 
ATG5, beclin-1 and ATG7, and hence reduce the autophagy process.30,31
3.2.2. Decreased lysosomal acidification—Decreased lysosomal acidification and 
lysosomal proteolytic activity due to reduction of hepatic cathepsin B and L levels impair 
the autophagic substrate degradation.27,32 Increased expression of asparagine synthetase 
(ASNS) due to ER stress and subsequent lysosomal calcium retention has also been reported 
to affect the lysosomal acidification and impair autophagy.33
3.2.3. Defective autophagosome-lysosome fusion—Increases in intracellular 
lipids alter the intracellular membrane lipid composition of both autophagosomes and 
lysosomes.34 This reduces the ability of autophagosomes to fuse with lysosomes and leads 
to a decrease in autophagic flux. Saturated fatty acids (FAs), such as palmitic acid (PA), post 
transcriptionally upregulate Rubicon (a beclin-1-interacting negative regulator for 
autophagosome-lysosome fusion), which then suppress the late state of autophagy fusion 
with lysosomes.28 The accumulation of saturated FA has also been recently proposed to 
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inhibit hepatic ATP2A2/SERCA2, an ER calcium pump that is responsible for the influx of 
cytosolic calcium into the ER lumen.35 Inhibition of ATP2A2/SERCA2 causes chronic 
increases in cytosolic calcium levels, which then arrests autophagy process by blocking the 
autophagic flux.35 Interestingly, a certain lipid, phosphatidic acid, restores autophagic 
function and hence significantly reduces hepatic lipid accumulation in HFD-induced 
NAFLD.36
3.2.4. Other mechanisms—Elevated levels of metabolites, such as S-
adenosylmethionine (SAMe) and methionine, during HFD can activate protein phosphatase 
2A (PP2A) by methylation and hence block autophagic flux.37 Similarly, over activation of 
mTORC1 due to inhibition of AMPK1 via sirtuin (SIRT) 3 activation also suppresses 
autophagy.38
4. Autophagy in ALD
Liver is the main organ responsible for alcohol metabolism. Oxidative metabolism of alcohol 
by alcohol dehydrogenase (ADH) (cytosol), cytochrome P450 (Cyp)2e1/Cyp1A2/Cyp3A4 
(ER, micro-somes) and catalase enzyme (peroxisomes) results in the generation of 
acetaldehyde and acetate.39 Oxidative metabolism of ethanol also produces reactive oxygen 
species (ROS), including hydroxyethyl, superoxide anion, and hydroxyl radicals all of which 
increase the risk of tissue damage.40 Alcohol oxidation generates a highly reduced cytosolic 
environment in liver cells (more nicotinamide adenine dinucleotide (reduced) (NADH)). 
Moreover, the NADH that is generated is oxidized by a series of chemical reactions in the 
mitochondrial electron transport chain, which further increases the free radicals and makes 
hepatocytes vulnerable to these toxic intermediates. The formation of protein adducts (by 
acetaldehyde, an alcohol metabolism intermediate) in hepatocytes impairs protein secretion, 
which has been proposed to play a role in the enlargement of the liver (i.e. hepatomegaly).40 
Ethanol also causes the accumulation of LDs and damages mitochondria, both of which can 
be regulated by autophagy.
4.1. Autophagy status in ALD
The effect of ethanol on autophagy is complex. Acute and chronic alcohol exposure may 
differentially regulate hepatic autophagy.41 Hepatic autophagy is activated in acute ethanol 
treatment but can be suppressed in chronic or high dose treatment of alcohol.23,42 An 
analysis of autophagy in primary cultured hepatocytes and a hepatic cell line treated with 
ethanol (20–80 mM for 6–24 h) showed increased autophagosome formation and autophagy 
flux, suggesting activation of cellular autophagy.43 Similar observations were made in the 
livers of mice that were fed with the acute binge ethanol feeding model (4–6 g ethanol/kg 
body weight).41,43 Acute ethanol feeding enhances the content of autophagic vacuoles, 
autophagosome-lysosomal fusion, and autophagic flux. Interestingly, the enhanced 
autophagy in acute ethanol fed mice was associated with a higher hepatic nuclear content of 
TFEB, which is considered to be a master regulator of transcription of genes in lysosome 
biogenesis and autophagy.17,41
Conflicting results have been reported about the autophagy status in the chronic ethanol 
feeding conditions. Chronic ethanol feeding (Lieber-DeCarli model) for 4 weeks or 10 
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weeks increases autophagosome numbers in rodent liver, suggesting the induction of 
autophagy.44,45 However, in another similar model, a chronic ethanol treatment, in which 
mice were fed ethanol for 10 days and ethanol concentration (as percent of total calories) 
was gradually increased from 3.6% on day 1to 7.2% on day 4, 10.2% on day 6, 21.6% on 
day 8, 29.2% (5.2% ethanol by volume) on day 10, the contents of hepatic autophagic 
vesicles were enhanced, but autophagic flux was lowered.41 This suggests that the chronic 
ethanol impairs autophagic flux and hence increases autophagic vesicles in the mouse liver. 
Impairments in autophagic flux have been similarly observed in a chronic plus binge ethanol 
feeding model (Gao-binge model: ethanol liquid diet for 10-day followed by a single binge 
of ethanol 5 g ethanol/kg body weight).23 In this study, the authors proposed that chronic 
ethanol induce insufficient autophagy, a novel autophagic flux scenario in which cells have a 
decreased number of lysosomes resulting in the accumulation of early autophagosomes. 
Mechanistically, chronic ethanol feeding was found to decrease the hepatic TFEB and 
lysosomal biogenesis in mouse livers. Earlier studies have also indicated that chronic ethanol 
exposure disrupts lysosome function and biogenesis.41,46 Overall, the various chronic 
ethanol feeding models implicate that even ethanol induces autophagy, due to the 
impairment of lysosomal function (TFEB suppression), and that autophagy activity is 
ultimately impaired during chronic alcohol consumption.
4.2. Mechanism of autophagy deregulation in ALD
In contrary to the autophagy inhibition during chronic alcohol treatment, the induction of 
autophagy in murine primary hepatocytes exposed to ethanol-induced autophagy process 
dependent on its metabolism, ROS production, and mTORC1 inhibition. Furthermore, 
autophagy protects hepatocytes against the detrimental effects of ethanol likely by removing 
damaged mitochondria and accumulated LDs. Acute ethanol-induced autophagy by the 
following mechanisms.
4.2.1. Increased ROS production—The metabolism of ethanol in hepatocytes by 
ADH and Cyp2e1 generates ROS that promotes autophagy probably via inactivation of 
ATG4B.47
4.2.2. mTORC1 suppression—Acute ethanol treatment suppresses the mTORC1 
complex.43 mTORC1 inhibition leads to activation of the downstream ULK1 complex to 
trigger autophagy, as described in Section 2.2.
Alcohol consumption also affects the TFEB, a transcriptional regulator of autophagy and 
lysosomal function. The differential effect of alcohol in autophagy process correlates with 
the cellular localization of TFEB.23,41 Acute ethanol treatment increases the nuclear protein 
levels of TFEB in mouse livers, correlating with the important role of TFEB in the induction 
of autophagy. In contrast, chronic alcohol treatment decreases nuclear TFEB proteins levels 
in mouse livers.41 A similar observation was made with the chronic feeding plus binge 
alcohol model, which mimicked consumption patterns of human alcoholics.23 Decreased 
TFEB was also observed in human ALD samples compared with healthy human donor liver 
samples.42 Mechanistically, ethanol was found to activate mTORC1 and decrease TFEB 
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proteins and the TFEB-mediated lysosomal biogenesis, resulting in insufficient autophagy in 
mouse livers.23 How TFEB protein level is downregulated is unknown.
Besides the TFEB transcription factor, alcohol also affects the transcription factor forkhead 
box O3a (FoxO3a) to modulate hepatic autophagy process.48 FoxO3a belongs to the O 
subfamily of the Fork head box protein family.49 The activity of FoxO3a is largely regulated 
by its multiple post-transcriptional modifications, including phosphorylation, acetylation, 
ubiquitination, and methylation.49 Acute ethanol treatment induce FoxO3a 
dephosphorylation (via Akt inhibition) and acetylation (due to an increase in the NADH/
nicotinamide adenine dinucleotide (oxidized) (NAD+) ratio and a decrease in hepatic SIRT 
1) in mouse liver and increase nuclear translocation of FoxO3a. Nuclear FoxO3a then 
elevates the transcription of many autophagy-related genes, such as ULK1, ATG5, beclin-1 
and ATG7, and thus induces autophagy in mouse liver.48 Interestingly, how FoxO3a 
coordinates with other autophagy-related transcription factors, such as TFEB and farnesoid 
X receptor (FXR), to regulate the expression of autophagy-related genes is unknown. 
However, the critical role of FoxO3 in ethanol-induced hepatic autophagy is well supported 
by the observation of blunted expression of autophagy-related genes, enhanced steatosis and 
liver injury in FoxO3a knock out mice.48
Chronic ethanol exposure was also reported to inhibit hepatocytes lipophagy through the 
inactivation of the small guanosine triphosphate Rab7 and reduced dynamin 2 activity, 
thereby causing depletion of lysosomes for LD breakdown.50,51 The inhibition of AMPK 
activity by chronic ethanol treatment may also be responsible for the suppression of 
autophagy.52 Mechanistically, in both acute and chronic alcohol treatment, there is an active 
involvement of ROS, mTOCR1, and TFEB in the regulation of autophagy process and 
lysosomal degradation function. The key role of ROS (nicotinamide adenine dinucleotide 
phosphate (reduced) (NADPH) oxidase-derived) in alcohol-induced liver disease is well 
established.53 Similarly, the counteracting relationship between the mTORC1 and TFEB is 
also well known (as described above in Section 2.2). However, how ROS generation in acute 
or chronic alcoholic condition systematically affects the mTORC1 activation or TFEB 
translocation is unclear. How ROS that are generated in acute alcohol treatment inhibits 
mTORC1, whereas chronic ethanol reactivates mTORC1 is also unknown. It is possible that 
the extent of ROS generation may modulate the activation status of mTORC1 and, hence, 
the autophagy process. Interventional studies using antioxidants, such as polyphenols and N-
acetyl cysteine, which neutralize the ROS generation under alcohol liver conditions, may be 
helpful in answering these questions.
5. Role of autophagy in steatosis and liver injury associated with NAFLD 
and ALD
Recent studies suggest that deregulated autophagy could play a role in the pathogenesis of 
alcoholic and non-alcoholic liver diseases. However, whether the deregulated autophagy is a 
cause or a consequence of the disease pathogenesis is less clear. Hepatic steatosis is an early 
histological observation in both alcoholic and non-alcoholic liver disease. There are varying 
degrees of hepatocyte injury that could be associated with inflammation and fibrosis. 
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Various lipid intermediates, such as FFAs (especially saturated), ceramides, cholesterol, 
diacyl-glycerol, phospholipid and lysophosphatidylcholine (LPC), which are significantly 
increased in liver tissue of NASH, have been observed to cause lipid toxicity.54 In chronic 
ethanol, hepatocyte injury is likely mediated by acetaldehyde-protein adducts and the 
hydroxyl free radical that are generated from ethanol metabolism.39 In general, hepatic lipid 
overload, mitochondrial dysfunction, ER stress, and the accumulation of protein aggregates 
have been implicated as important stimuli of hepatocyte cell death and thus liver injury. 
However, the extent of liver injury that is generally observed in vivo animal study or human 
clinical observation is mild. Recently, the concept of sublethal lipotoxic hepatocyte injury 
has been proposed.55 Lipid accumulation cause hepatocyte stress and dysfunction of an 
insufficient magnitude to cause cell death but enough to induce pro-apoptotic signaling that 
results in the release of various aberrant pro-inflammatory signaling molecules via 
extracellular vehicles (EVs).55
The primary role of autophagy is to degrade intracellular organelles and protein aggregates 
that are too large to be broken down by the proteasome. Thus, the defect in autophagy either 
due to the high-fat diet or the chronic alcohol can contribute to disease (initiation or 
progression) by two general mechanisms: (i) the accumulation of potentially dangerous 
autophagic substrates and (ii) the lack of potentially beneficial autophagic products or 
functions. Followings are three possible major routes through which autophagy could 
ameliorate the pathogenesis of alcohol or non-alcoholic liver disease (Fig. 2).
5.1. Autophagy lowers hepatic lipid load by lipophagy
A seminal study by Czaja and colleagues24 in 2009 demonstrated that hepatocytes consume 
intracellular lipid when they are starved. Intracellular lipids (triglyceride and cholesterol) are 
stored as LDs. Under conditions of stress, autophagy promotes lipid hydrolysis and 
generates FFAs by releasing the content of LDs to lysosomes for degradation. Based on this 
concept, inhibition of autophagy can potentially lead to the accumulation of fat, which is 
potentially toxic to cells. Alternatively, the activation of autophagy pharmacologically or 
genetically could alleviate the intrahepatic lipid load and hence decrease the cellular stress.
44,56
5.2. Autophagy clears dysfunctional or damaged mitochondria by mitophagy
Mitochondria is actively involved in the hepatic metabolism of ethanol or lipid (from high-
fat diet). There is a considerable evidence from both human and animal studies that, during 
the oxidative metabolism of ethanol or lipid, mitochondria are intimately involved in the 
generation of ROS. Mitochondria are themselves also targets of oxidative stress that can 
deregulate the cellular energy balance. The vicious cycle of ROS generation through 
oxidative metabolism and mitochondrial damage leads to the promotion of hepatocyte’s 
apoptotic or necrotic death and hence cause liver injury. Alternatively, activation of 
autophagy/ mitophagy can help to eliminate these dysfunctional or damaged mitochondria 
and hence reduce the ROS level and potentially alleviate the disease. The PTEN-induced 
kinase 1 (PINK1)-Parkin mediated mitophagy is well-studied pathway particularly in the 
context of ALD. Ethanol causes a marked increase in the number of mitophagic vacuoles in 
the hepatocytes following ethanol treatment, suggesting selective induction of hepatic 
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mitophagy.43,57 Mitophagy is initiated by accumulation of PINK1 at the outer membrane of 
damaged mitochondria, resulting in the recruitment of cytoplasmic Parkin (an E3 ubiquitin 
ligase) to those mitochondria.58 The PINK1-Parkin protein interaction in damaged 
mitochondria initiates ubiquitination of mitochondrial outer membrane proteins and 
subsequent mitochondrial degradation by LC3-mediated autophagosomes. The important 
protective role of PINK1-Parkin mediated mitophagy in ALD is supported by the 
observation made with the ethanol-treated Parkin knock out mice. Parkin knock out mice 
had increased liver injury, oxidative stress, and steatosis after alcohol treatment compared 
with wild-type mice.59 At a cellular level, Parkin knock out hepatocytes had severely 
swollen and damaged mitochondria that lacked cristae, decreased mitophagy, β-oxidation, 
mitochondria respiration, and cytochrome c oxidase activity after acute ethanol treatment.59
5.3. Clearance of Mallory-Denk bodies (MDBs) by proteophagy
MDBs are cytoplasmic hyaline inclusion in the hepatocytes, generally considered as an 
indicator of histological severity in ALD and NAFLD.60,61 The major components of MDBs 
include keratin 8, keratin 18, ubiquitin, and p62.61 ROS released from the oxidative 
metabolism of ethanol or through excessive fat metabolism can potentially affect many 
intracellular proteins resulting in the formation of MDBs which could be potentially 
damaging to hepatic structure and function. Even though the mechanisms of MDBs 
formation is less clear, there is emerging evidence that autophagy apparently participates in 
the elimination of components of MDB.62,63 Pharmacological activation of autophagy by 
rapamycin prevents MDB formation and also causes MDB resorption.63
6. Pharmacological modulation of autophagy
Alterations in autophagy or autophagy related processes occur in fatty liver situation, which 
support the possibility that pharmacological activators of autophagy could be beneficial for 
NAFLD and ALD patients. The potential benefit of autophagy-enhancing agents to reduce 
fatty liver conditions and liver injury has been reported in murine models of NAFLD and 
ALD.44 Several pharmacological and nutritional supplements are available to modulate 
autophagy. However, these agents modulate autophagy though multipronged or hitherto 
uncharacterized molecular mechanisms. Moreover, recent studies indicate that autophagy 
may play a different role in hepatocytes and hepatic non-parenchymal cells, which results in 
opposite effects on liver disease.64,65 For example, in liver fibrosis, the activation of 
autophagy may be pro-fibrotic (due to stellate cell activation) as well as anti-fibrotic 
(Kupffer cells and hepatocytes). Thus, targeting autophagy in a hepatic cell-specific manner 
is one of the main challenges for future therapeutic approaches for liver diseases. Further 
characterization of dysfunctional autophagy in different stages of liver diseases will offer 
new avenues for future drug development.
The first preclinical study to show the potential utility of stimulating autophagy to improve 
liver pathologies in NAFLD and ALD was performed by Lin et al.44 using two well 
established autophagy inducers: carbamazepine and rapamycin. Carbamazepine and 
rapamycin induce autophagy in hepatocytes in vitro and in vivo. When mice that have been 
fed with HFD or chronic ethanol, are injected with carbamazepine or rapamycin, hepatic 
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steatosis, liver injury, and other metabolic parameters, such as serum triglycerides and 
insulin resistance, are alleviated. In contrast, chloroquine, which blocks autophagy, 
exacerbates steatosis and injury in these animals.44 Besides, rapamycin, various rapalogs, 
such as Torin 1, PP242, AZD3147, Z1001, rottlerin, XL388, AP23573, and RAD001 have 
also been identified as autophagy inducers.66 However, the impact of these autophagy 
inducers in the prevention and treatment of NAFLD and ALD are yet to be tested in 
established preclinical models.
Several nutritional supplements, such as caffeine, resveratrol, Vitamin D and retinoic acid, 
improve hepatic steatosis by inducing autophagy.67–69 Vitamin D protects against HFD-
induced liver steatosis by inducing autophagy by upregulating ATG16L1 in mice.69 
Glycycoumarin (coumarin isolated from natural product licorice) inhibits hepatocyte 
lipoapoptosis through reactivation of impaired autophagy.70 Acutely activating autophagy by 
caloric restriction or physical exercise also improves hepatic steatosis and other various 
metabolic parameters (insulin sensitivity, body weight).71 In addition to pharmacological or 
nutritional activation of autophagy, genetic reconstitution of autophagy also attenuates 
steatosis.30,56
7. Conclusions
Autophagy plays a crucial role in liver homeostasis, and hence, the deregulation of 
autophagy could play a crucial role in the pathogenesis of alcoholic and non-alcoholic liver 
disease. However, it is still unclear how autophagy is deregulated under these conditions. 
Better understanding of the mechanisms of deregulation of autophagy during acute or 
chronic alcoholic conditions and NAFLD will further assist in designing and developing 
autophagy specific therapeutics in a near future.
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Fig. 1. Overview of cellular autophagy.
In macroautophagy, phagophore formation and elongation sequester the autophagic cargoes 
and forms autophagosomes. The autophagosome then fuses with the lysosome to form 
autolysosomes. In microautophagy, substrates are directly engulfed by the lysosomal 
membrane. In CMA, proteins with the pentapeptide motif KFERQ are selectively 
recognized by the HSC70 chaperone. Substrate-bound HSC70 then interacts with LAMP-2A 
in lysosome membrane and subsequently translocates into the lysosomal lumen. In all three 
processes, the cargos are ultimately degraded by lysosomal hydrolases, to release smaller 
biomolecules for reutilization. Abbreviations: CMA, chaperonin mediated autophagy; 
HSC70, heat shock cognate 70; LAMP-2A, lysosome-associated membrane glycoprotein 
2A.
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Fig. 2. Role of autophagy in steatosis and liver injury associated with NAFLD and ALD.
NAFLD and ALD are marked by hepatic steatosis, liver injury, inflammation, fibrosis, 
cirrhosis, and HCC. Alcohol consumption or a high-fat diet impairs autophagy, resulting in 
intracellular accumulation of damaged mitochondria, MDBs, and excessive LDs. Autophagy 
relieves hepatocellular steatosis and liver injury by degrading these intracellular toxic 
components. The up and down black arrows indicate increased and decreased in individual 
level or activity. Abbreviations: NAFLD, non-alcoholic fatty liver disease; ALD, alcoholic 
liver disease; HCC, hepatocellular carcinoma; MDBs, Mallory-Denk bodies; LDs, lipid 
droplets.
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